[go: up one dir, main page]

DE60019902D1 - Echinocandin pharmazeutische zusammensetzungen - Google Patents

Echinocandin pharmazeutische zusammensetzungen

Info

Publication number
DE60019902D1
DE60019902D1 DE60019902T DE60019902T DE60019902D1 DE 60019902 D1 DE60019902 D1 DE 60019902D1 DE 60019902 T DE60019902 T DE 60019902T DE 60019902 T DE60019902 T DE 60019902T DE 60019902 D1 DE60019902 D1 DE 60019902D1
Authority
DE
Germany
Prior art keywords
echinocandin
formulations
pharmaceutical compositions
freeze
solution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60019902T
Other languages
English (en)
Inventor
Nathaniel Milton
Philip Moder
Lawrence Sabatowski
Ann Sweetana
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22403808&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE60019902(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Application granted granted Critical
Publication of DE60019902D1 publication Critical patent/DE60019902D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
DE60019902T 1999-03-03 2000-03-02 Echinocandin pharmazeutische zusammensetzungen Expired - Lifetime DE60019902D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12262399P 1999-03-03 1999-03-03
PCT/US2000/005546 WO2000051564A1 (en) 1999-03-03 2000-03-02 Echinocandin pharmaceutical formulations containing micelle-forming surfactants

Publications (1)

Publication Number Publication Date
DE60019902D1 true DE60019902D1 (de) 2005-06-09

Family

ID=22403808

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60019902T Expired - Lifetime DE60019902D1 (de) 1999-03-03 2000-03-02 Echinocandin pharmazeutische zusammensetzungen

Country Status (19)

Country Link
US (2) US6960564B2 (de)
EP (2) EP1582204B1 (de)
JP (2) JP4936595B2 (de)
KR (1) KR100613136B1 (de)
CN (1) CN100335122C (de)
AT (1) ATE294571T1 (de)
AU (1) AU776782C (de)
BR (1) BRPI0009249B8 (de)
CA (1) CA2362481C (de)
CY (2) CY1114631T1 (de)
DE (1) DE60019902D1 (de)
DK (1) DK1582204T3 (de)
ES (1) ES2433678T3 (de)
HK (1) HK1040062A1 (de)
IL (1) IL145185A0 (de)
PT (1) PT1582204E (de)
RU (1) RU2250763C2 (de)
WO (1) WO2000051564A1 (de)
ZA (1) ZA200108002B (de)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6743777B1 (en) * 1992-03-19 2004-06-01 Eli Lilly And Company Cyclic peptide antifungal agents and process for preparation thereof
JP2003511345A (ja) 1998-12-09 2003-03-25 イーライ リリー アンド カンパニー Ｅｃｈｉｎｏｃａｎｄｉｎシクロペプチド化合物の精製
KR20020003864A (ko) 1999-03-03 2002-01-15 피터 지. 스트링거 에키노칸딘/탄수화물 착물
RU2250763C2 (ru) 1999-03-03 2005-04-27 Эли Лилли Энд Компани Фармацевтические препараты эхинокандина, содержащие мицелообразующие поверхностно-активные вещества
IL145186A0 (en) 1999-03-03 2002-06-30 Lilly Co Eli Formation and anion-exchange of crystalline echinocandin ammonium salts
BR0008713A (pt) 1999-03-03 2001-12-26 Lilly Co Eli Processos para preparar formulações ecomposições farmacêuticas orais com ecb
TWI233805B (en) * 1999-07-01 2005-06-11 Fujisawa Pharmaceutical Co Stabilized pharmaceutical composition in lyophilized form as antifungal agent
CN1268321C (zh) * 2001-07-13 2006-08-09 那野伽利阿株式会社 内部包有药物的高分子胶束的冻结干燥用组合物和该胶束的制备方法
JP2003342168A (ja) * 2002-05-24 2003-12-03 Nano Career Kk 注射用薬物含有ポリマーミセル製剤の製造方法
US6991800B2 (en) 2002-06-13 2006-01-31 Vicuron Pharmaceuticals Inc. Antifungal parenteral products
US7754230B2 (en) * 2004-05-19 2010-07-13 The Regents Of The University Of California Methods and related compositions for reduction of fat
ES2660172T3 (es) 2004-05-19 2018-03-21 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Composición inyectable que comprende desoxicolato de sodio
US20060127468A1 (en) 2004-05-19 2006-06-15 Kolodney Michael S Methods and related compositions for reduction of fat and skin tightening
CN100579510C (zh) * 2006-04-13 2010-01-13 新疆维吾尔自治区包虫病临床研究所 新型前体胶束制剂及其生产方法
EP2170362B1 (de) * 2007-06-26 2015-11-04 Merck Sharp & Dohme Corp. Lyophilisierte antipilzzusammensetzung
US20090238867A1 (en) * 2007-12-13 2009-09-24 Scott Jenkins Nanoparticulate Anidulafungin Compositions and Methods for Making the Same
CN102026621A (zh) * 2008-05-15 2011-04-20 巴克斯特国际公司 稳定的药物制剂
US8101593B2 (en) 2009-03-03 2012-01-24 Kythera Biopharmaceuticals, Inc. Formulations of deoxycholic acid and salts thereof
EP2521539A4 (de) * 2009-12-31 2014-11-26 Mannkind Corp Injizierbare formulierungen zur parenteralen verabreichung
CN102618606B (zh) * 2011-01-30 2014-09-10 浙江海正药业股份有限公司 一种棘白菌素生物转化方法
CN102614492B (zh) * 2011-01-31 2013-12-11 上海天伟生物制药有限公司 一种含有棘白菌素类抗真菌剂米卡芬净的液体药用组合物
WO2012112940A1 (en) 2011-02-18 2012-08-23 Kythera Biopharmaceuticals, Inc. Treatment of submental fat
SI2680873T1 (sl) 2011-03-03 2017-12-29 Cidara Therapeutics, Inc. Protiglivna sredstva in njihova uporaba
US8653058B2 (en) 2011-04-05 2014-02-18 Kythera Biopharmaceuticals, Inc. Compositions comprising deoxycholic acid and salts thereof suitable for use in treating fat deposits
CN103386117B (zh) * 2011-09-26 2015-09-30 上海天伟生物制药有限公司 一种低杂质含量的卡泊芬净制剂及其制备方法和用途
CN103315969B (zh) * 2011-09-26 2016-05-18 上海天伟生物制药有限公司 一种低杂质含量的卡泊芬净制剂及其制备方法和用途
MX2014008390A (es) * 2012-01-12 2014-09-22 Celgene Corp Formulaciones de romidepsina y sus usos.
PL3677252T3 (pl) 2012-03-19 2024-01-08 Cidara Therapeutics, Inc. Schematy dawkowania dla związków z klasy echinokandyn
CN103570530B (zh) * 2012-07-26 2016-08-10 鲁南新时代生物技术有限公司 一种阿尼芬净侧链中间体的制备方法
SG10201902598VA (en) * 2014-09-24 2019-04-29 Aileron Therapeutics Inc Peptidomimetic macrocycles and formulations thereof
WO2016079749A2 (en) * 2014-11-19 2016-05-26 Gufic Biosciences Limited Process for preparation of parenteral formulation of anidulafungin
CN105641678A (zh) * 2014-12-03 2016-06-08 博瑞生物医药（苏州）股份有限公司 阿尼芬净胃肠外制剂及制备方法
PL3058958T3 (pl) 2015-02-23 2019-02-28 Selectchemie Ag Kompozycja anidulafunginy
GR1008818B (el) 2015-05-22 2016-08-01 Φαρματεν Ανωνυμος Βιομηχανικη Και Εμπορικη Εταιρεια Φαρμακευτικων Ιατρικων Και Καλλυντικων Προϊοντων Φαρμακευτικο σκευασμα περιεχον εναν αντιμυκητιασικο παραγοντα εχινοκανδινης και μεθοδος παρασκευης αυτου
US11318110B2 (en) 2015-08-28 2022-05-03 Caliway Biopharmaceuticals Co., Ltd. Pharmaceutical composition for reducing local fat and uses thereof
CN119157850A (zh) 2015-08-28 2024-12-20 康霈生技股份有限公司 用于减少局部脂肪的医药组成物及其用途
WO2017037232A1 (en) * 2015-09-02 2017-03-09 Xellia Pharmaceuticals Aps Anidulafungin formulations
ES2955711T3 (es) 2016-03-16 2023-12-05 Cidara Therapeutics Inc Regímenes de dosificación para el tratamiento de infecciones fúngicas
CN111050798A (zh) 2017-07-12 2020-04-21 奇达拉治疗公司 用于治疗真菌感染的组合物和方法
CN109574811B (zh) * 2018-11-22 2021-12-24 中山大学 一种阿尼芬净侧链中间体对戊氧基三联苯甲酸的制备方法
CN109481665B (zh) * 2018-12-05 2019-08-06 广州迈达康医药科技有限公司 一种注射用阿尼芬净复溶药剂及其制备方法
MX2022006085A (es) 2019-11-22 2023-03-01 Leiutis Pharmaceuticals Llp Formulaciones parenterales estables de duloxetina.
AU2023370368A1 (en) 2022-10-25 2025-06-05 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Pharmaceutical composition comprising echinocandin analog and preparation method for pharmaceutical composition

Family Cites Families (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2002A (en) * 1841-03-12 Tor and planter for plowing
US3293482A (en) * 1962-06-21 1966-12-20 Rca Corp Plural output traveling wave tube
JPS5134916B2 (de) * 1974-03-06 1976-09-29
JPS5668616A (en) * 1979-11-08 1981-06-09 Yukio Kimura Preparation of antibiotic composition
US4293489A (en) * 1979-12-13 1981-10-06 Eli Lilly And Company Derivatives of A-30912A nucleus
US4293482A (en) * 1979-12-13 1981-10-06 Eli Lilly And Company A-30912A Nucleus
US4293483A (en) * 1979-12-13 1981-10-06 Eli Lilly And Company Derivatives of A-30912A nucleus
US4320052A (en) * 1979-12-13 1982-03-16 Eli Lilly And Company Derivatives of A-30912A nucleus
US4299763A (en) * 1979-12-13 1981-11-10 Eli Lilly And Company A-30912B Nucleus
US4304716A (en) * 1979-12-13 1981-12-08 Eli Lilly And Company S 31794/F-1 Nucleus
CA1183127A (en) 1979-12-13 1985-02-26 Manuel Debono Process for the preparation of derivatives of cyclic peptide nuclei
CA1170598A (en) 1979-12-13 1984-07-10 Bernard J. Abbott Process for the preparation of cyclic peptide nuclei
US4348384A (en) * 1980-10-17 1982-09-07 Dainippon Pharmaceutical Co., Ltd. Pharmaceutical composition for oral administration containing coagulation factor VIII or IX
US5141674A (en) * 1984-03-08 1992-08-25 Phares Pharmaceutical Research N.V. Methods of preparing pro-liposome dispersions and aerosols
US4876241A (en) * 1987-05-22 1989-10-24 Armour Pharmaceutical Company Stabilization of biological and pharmaceutical products during thermal inactivation of viral and bacterial contaminants
US5000000A (en) * 1988-08-31 1991-03-19 University Of Florida Ethanol production by Escherichia coli strains co-expressing Zymomonas PDC and ADH genes
DK173802B1 (da) 1988-09-12 2001-11-05 Merck & Co Inc Præparat til behandling af Pneumocystis carinii infeksioner og anvendelse af et cyclohexapeptid til fremstilling af et lægemiddel mod Pneumocystis carinii infektioner
US5166135A (en) * 1988-09-12 1992-11-24 Merck & Company, Inc. Method for the control of pneumocystis carinii
US4927831A (en) * 1988-10-20 1990-05-22 American Home Products Spiro-isoquinoline-pyrrolidine tetrones and analogs thereof useful as aldose reductase inhibitors
AU617541B2 (en) 1988-10-20 1991-11-28 Wyeth Spiro-isoquinoline-pyrrolidine tetrones and analogs thereof useful as aldose reductase inhibitors
CA2011365A1 (en) 1989-03-06 1990-09-06 Eugene L. Inman Diluent formulation for daptomycin
US5202309A (en) * 1989-06-30 1993-04-13 Merck & Co., Inc. Antibiotic cyclopeptide fermentation product
JP2844351B2 (ja) * 1989-07-13 1999-01-06 株式会社科薬 安定なポリミキシン系抗生物質水性溶液
JPH03240727A (ja) * 1990-02-15 1991-10-28 Toyo Jozo Co Ltd ニューモシスチス・カリニ肺炎治療剤
CA2037957A1 (en) 1990-03-12 1991-09-13 Merck & Co., Inc. N-acylated cyclohexapeptide compounds
GB2241956A (en) 1990-03-16 1991-09-18 Merck & Co Inc N-acylated cyclohexapeptide compounds
US5049546A (en) 1990-03-19 1991-09-17 Merck & Co., Inc. Antibiotic agents
US5386009A (en) 1990-03-19 1995-01-31 Merck & Co. Inc. Lipopeptide derivatives
IL97347A0 (en) 1990-03-19 1992-05-25 Merck & Co Inc Lipopeptide derivatives and antimicrobial compositions containing them
US5330973A (en) 1990-03-19 1994-07-19 Merck & Co., Inc. Lipopeptide derivatives
IE910892A1 (en) 1990-03-19 1991-09-25 Merck & Co Inc Lipopeptide compounds
US5310726A (en) 1990-03-19 1994-05-10 Merck & Co., Inc. Lipopeptide compounds
DK0460882T3 (da) 1990-06-07 1996-08-26 Lilly Co Eli Lipopeptiddeacylase
IL98506A (en) * 1990-06-18 1996-09-12 Fujisawa Pharmaceutical Co Cyclic peptide antibiotics processes for the preparation thereof and pharmaceutical compositions containing them
US5198421A (en) * 1991-04-26 1993-03-30 Merck & Co., Inc. Phosphorylated cyclic lipopeptide
EP0486011A3 (en) 1990-11-16 1992-07-15 Fujisawa Pharmaceutical Co., Ltd. Pharmaceutical composition against pneumocystis carinii
US5369093A (en) 1991-03-15 1994-11-29 Merck & Co., Inc. Lipopeptide derivatives
US5993805A (en) * 1991-04-10 1999-11-30 Quadrant Healthcare (Uk) Limited Spray-dried microparticles and their use as therapeutic vehicles
US5136783A (en) * 1991-05-23 1992-08-11 Blount, Inc. Chain saw sprocket
US5233023A (en) 1991-07-30 1993-08-03 Merck & Co., Inc. Process for phosphate ester compounds of certain cyclohexapeptides
JPH05271097A (ja) * 1991-10-07 1993-10-19 Asahi Chem Ind Co Ltd アクレアシン類の可溶化剤および医薬組成物
US6743777B1 (en) * 1992-03-19 2004-06-01 Eli Lilly And Company Cyclic peptide antifungal agents and process for preparation thereof
US6384013B1 (en) * 1992-03-19 2002-05-07 Eli Lilly And Company Cyclic peptide antifungal agents and process for preparation thereof
US5965525A (en) * 1992-03-19 1999-10-12 Eli Lilly And Company Cyclic peptide antifungal agents
NZ247149A (en) * 1992-03-19 1996-10-28 Lilly Co Eli Cyclic peptide antifungal agents and compositions thereof
EP0589074B1 (de) 1992-09-22 2001-11-21 Takeo Dr. Takayanagi Kohlenhydrate-Komplexe zur Vernichtung von Krebszellen
ES2079994B1 (es) * 1992-10-07 1996-08-01 Cusi Lab Formulacion farmaceutica a base de polimixina-trimetoprim y un agente antiinflamatorio para su utilizacion topica oftalmica y otica.
JPH06172205A (ja) * 1992-12-11 1994-06-21 Asahi Chem Ind Co Ltd アクレアシン類含有脂肪乳剤
US6268338B1 (en) * 1993-04-30 2001-07-31 Merck & Co., Inc. Cyclohexapeptidyl amine compounds
JPH09500103A (ja) * 1993-05-04 1997-01-07 メルク エンド カンパニー インコーポレーテッド シクロヘキサペプチジルアミノアルキルエーテル
IS1796B (is) * 1993-06-24 2001-12-31 Ab Astra Fjölpeptíð lyfjablanda til innöndunar sem einnig inniheldur eykjaefnasamband
US5541160A (en) * 1994-04-04 1996-07-30 Merck & Co., Inc. Antifungal and anti-pneumocystis compounds, compositions containing such compounds, and methods of use
GB9501841D0 (en) * 1995-01-31 1995-03-22 Co Ordinated Drug Dev Improvements in and relating to carrier particles for use in dry powder inhalers
US5646111A (en) * 1995-04-07 1997-07-08 Eli Lilly And Company Cyclic peptide antifungal Agents
US5652213A (en) 1995-05-26 1997-07-29 Eli Lilly And Company Cyclic peptide antifungal agents
US5629290A (en) * 1995-05-26 1997-05-13 Eli Lilly And Company Cyclic peptide antifungal agents
US5618787A (en) 1995-05-26 1997-04-08 Eli Lilly And Company Cyclic peptide antifungal agents
US5786325A (en) * 1995-05-26 1998-07-28 Eli Lilly And Company Cyclic peptide antifungal agents and methods of making and using
GB9515182D0 (en) * 1995-07-24 1995-09-20 Co Ordinated Drug Dev Improvements in and relating to powders for use in dry powder inhalers
US5629289A (en) 1995-07-25 1997-05-13 Eli Lilly And Company Cyclic peptide antifungal agents
US6267958B1 (en) * 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
FR2740686B1 (fr) * 1995-11-03 1998-01-16 Sanofi Sa Formulation pharmaceutique lyophilisee stable
CA2244238A1 (en) 1996-02-01 1997-08-07 Eli Lilly And Company Cyclic peptide antifungal agents
US5693611A (en) * 1996-02-01 1997-12-02 Eli Lilly And Company Cyclic peptide antifungal agents
US6245349B1 (en) * 1996-02-23 2001-06-12 éLAN CORPORATION PLC Drug delivery compositions suitable for intravenous injection
AR006598A1 (es) * 1996-04-19 1999-09-08 Merck Sharp & Dohme "composiciones anti-fungosas, su uso en la manufactura de medicamentos y un procedimiento para su preparación"
US5952300A (en) * 1996-04-19 1999-09-14 Merck & Co., Inc. Antifungal compositions
US5985309A (en) * 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
US5696084A (en) * 1996-08-16 1997-12-09 Abbott Laboratories Amino-lipopetide antifungal agents
FR2755857B1 (fr) * 1996-11-19 1998-12-24 Rhone Poulenc Rorer Sa Compositions pharmaceutiques stabilisees, a base de quinupristine et de dalfopristine et leur preparation
AUPO381496A0 (en) * 1996-11-25 1996-12-19 Fujisawa Pharmaceutical Co., Ltd. New compound
US5976574A (en) * 1996-12-31 1999-11-02 Inhale Therapeutic Systems Processes for spray drying hydrophobic drugs in organic solvent suspensions
AUPO691897A0 (en) * 1997-05-21 1997-06-12 Fujisawa Pharmaceutical Co., Ltd. New compound
WO1999006062A1 (en) 1997-08-04 1999-02-11 Eli Lilly And Company Cyclic peptide antifungal agents
US5972996A (en) * 1997-08-22 1999-10-26 Merck & Co., Inc. 4-cyano-4-deformylsordarin derivatives
US6309623B1 (en) * 1997-09-29 2001-10-30 Inhale Therapeutic Systems, Inc. Stabilized preparations for use in metered dose inhalers
US6433040B1 (en) * 1997-09-29 2002-08-13 Inhale Therapeutic Systems, Inc. Stabilized bioactive preparations and methods of use
US6565885B1 (en) * 1997-09-29 2003-05-20 Inhale Therapeutic Systems, Inc. Methods of spray drying pharmaceutical compositions
CA2255140A1 (en) 1997-12-23 1999-06-23 Eli Lilly And Company Echinocandin binding domain of 1,3-.beta.-glucan synthase
US6323176B1 (en) * 1998-02-25 2001-11-27 Eli Lilly And Company Cyclic peptide antifungal agents
US6284282B1 (en) * 1998-04-29 2001-09-04 Genentech, Inc. Method of spray freeze drying proteins for pharmaceutical administration
US6423345B2 (en) * 1998-04-30 2002-07-23 Acusphere, Inc. Matrices formed of polymer and hydrophobic compounds for use in drug delivery
US6451349B1 (en) * 1998-08-19 2002-09-17 Quadrant Healthcare (Uk) Limited Spray-drying process for the preparation of microparticles
ATE287899T1 (de) * 1998-08-20 2005-02-15 Lilly Co Eli Verfahren zur herstellung von ring-modifizierten zyklischen peptidanalogen
EP1107982B1 (de) 1998-08-28 2004-05-19 Eli Lilly & Company Reversible borkomplexe von 1,2-(cis)-diol zyklischen peptiden
US6660843B1 (en) * 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
JP2003511345A (ja) 1998-12-09 2003-03-25 イーライ リリー アンド カンパニー Ｅｃｈｉｎｏｃａｎｄｉｎシクロペプチド化合物の精製
EP1140991A1 (de) 1998-12-16 2001-10-10 Eli Lilly And Company Fungizide in form zyklischer peptide
JP2002532513A (ja) 1998-12-16 2002-10-02 イーライ リリー アンド カンパニー 糖置換基を有する環式ペプチド抗真菌剤
US20030104048A1 (en) * 1999-02-26 2003-06-05 Lipocine, Inc. Pharmaceutical dosage forms for highly hydrophilic materials
RU2250763C2 (ru) * 1999-03-03 2005-04-27 Эли Лилли Энд Компани Фармацевтические препараты эхинокандина, содержащие мицелообразующие поверхностно-активные вещества
KR20020003864A (ko) 1999-03-03 2002-01-15 피터 지. 스트링거 에키노칸딘/탄수화물 착물
BR0008713A (pt) 1999-03-03 2001-12-26 Lilly Co Eli Processos para preparar formulações ecomposições farmacêuticas orais com ecb
IL145186A0 (en) * 1999-03-03 2002-06-30 Lilly Co Eli Formation and anion-exchange of crystalline echinocandin ammonium salts
US6258821B1 (en) * 1999-04-26 2001-07-10 Medimmune Oncology, Inc. Compositions comprising trimetrexate and methods of their synthesis and use
US7914799B2 (en) * 2001-08-27 2011-03-29 Immunitor USA, Inc. Anti-fungal composition
US6991800B2 (en) * 2002-06-13 2006-01-31 Vicuron Pharmaceuticals Inc. Antifungal parenteral products

Also Published As

Publication number Publication date
CA2362481A1 (en) 2000-09-08
EP1582204B1 (de) 2013-09-25
JP2005325142A (ja) 2005-11-24
BRPI0009249B8 (pt) 2021-07-06
RU2250763C2 (ru) 2005-04-27
EP1582204A3 (de) 2007-10-10
AU3249100A (en) 2000-09-21
BRPI0009249B1 (pt) 2011-11-29
US20050192213A1 (en) 2005-09-01
AU776782B2 (en) 2004-09-23
US6960564B2 (en) 2005-11-01
CY2014003I2 (el) 2015-12-09
PT1582204E (pt) 2013-11-25
CN1345229A (zh) 2002-04-17
HK1040062A1 (zh) 2002-05-24
CA2362481C (en) 2008-11-04
AU776782C (en) 2005-04-07
CY1114631T1 (el) 2015-12-09
EP1582204A2 (de) 2005-10-05
WO2000051564A8 (en) 2002-05-30
CN100335122C (zh) 2007-09-05
EP1156782B1 (de) 2005-05-04
ES2433678T3 (es) 2013-12-12
JP4755464B2 (ja) 2011-08-24
US7709444B2 (en) 2010-05-04
ZA200108002B (en) 2003-06-25
KR20010111570A (ko) 2001-12-19
JP4936595B2 (ja) 2012-05-23
BRPI0009249A (pt) 2001-11-20
CY2014003I1 (el) 2015-12-09
WO2000051564A1 (en) 2000-09-08
KR100613136B1 (ko) 2006-08-17
DK1582204T3 (da) 2013-11-04
ATE294571T1 (de) 2005-05-15
US20030054981A1 (en) 2003-03-20
EP1156782A1 (de) 2001-11-28
JP2002538095A (ja) 2002-11-12
HK1074803A1 (en) 2005-11-25
IL145185A0 (en) 2002-06-30

Similar Documents

Publication Publication Date Title
ATE294571T1 (de) Echinocandin pharmazeutische zusammensetzungen
ECSP045496A (es) "preparaciones acidas de insulina con estabilidad mejorada"
EA200501001A1 (ru) Фармацевтический состав с нерастворимым активным агентом
WO2008150479A3 (en) High temperature stable peptide formulation
NO994409D0 (no) Stabilisering av syresensitive benzimidazoler med aminosyre/cyklodekstrin-kombinasjoner
AR033059A1 (es) Preparados de insulina exentos de zinc y pobres en zinc, con estabilidad mejorada.
AR043863A1 (es) Composiciones que contienen piperacilina y tazobactam, utiles para inyeccioines
DE69418468D1 (de) Viskoelastische zusammensetzungen aus organischen fluorierten verbindungen
WO2001064187A3 (en) Anaesthetic formulations
DK1157030T3 (da) Enchinocanidin/carbohydratkomplekser
DK1280558T3 (da) Halvfast indgivelsesvehikel og farmaceutiske sammensætninger
KR970705978A (ko) 가역성열겔화 수용성 의약 조성물을 함유하는 동결건조 제제(Lyophilized pharmaceutical preparations capable of providing aqueous drug composition having property of reversible thermosetting gelation)
AR039388A1 (es) Formulaciones liquidas de baja dosis de entecavir y uso
BRPI0418115A (pt) formulação lìquida estável de hormÈnio de crescimento
AR014772A1 (es) Una formulacion acuosa que permite la estabilizacion de conjugados de peg-interferon alfa durante y despues de la liofilizacion, proceso para producir un polvo liofilizado, un polvo liofilizado, un proceso para producir una solucion de los conjudados peg-interferon-alfa y un articulo de manufactura
ATE367165T1 (de) Xanthangummi enthaltende reepithelialisierende pharmazeutische zubereitungen
PE20030545A1 (es) Formulaciones de jarabe de ribavirina
DE60316714D1 (de) Pharmazeutische formulierung enthaltend olanzapin
AU3548901A (en) Veterinary compositions for the treatment of parasitic diseases
AR044697A1 (es) Formulaciones farmaceuticas que comprenden amoxicilina y clavulanato
RU2001100069A (ru) Антгельминтное средство
BR0108732A (pt) Composição farmacêutica para a prevenção e tratamento da progressão da fibrose e cirrose hepática, seu uso e método para a prevenção e tratamento da fibrose e cirrose hepática
WO2001003774A3 (en) Pharmaceutical composition for the treatment of calcification
ES2118033B1 (es) Formulacion farmaceutica antiinflamatoria.
ECSP982396A (es) Composiciones que contienen tetrahidrolipstatina